Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec

The discovery of EGFR tyrosine kinase inhibitors (TKI) for the treatment of EGFR mutant (EGFRm) metastatic NSCLC is regarded as a landmark in lung cancer. EGFR-TKIs have now become a standard first-line treatment for EGFRm NSCLC. The aim of this retrospective cohort study is to describe real-world p...

Descripción completa

Detalles Bibliográficos
Autores principales: Agulnik, Jason S., Kasymjanova, Goulnar, Pepe, Carmela, Hurry, Manjusha, Walton, Ryan N., Sakr, Lama, Cohen, Victor, Small, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700535/
https://www.ncbi.nlm.nih.gov/pubmed/34940073
http://dx.doi.org/10.3390/curroncol28060434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700535/
https://www.ncbi.nlm.nih.gov/pubmed/34940073
http://dx.doi.org/10.3390/curroncol28060434

Ejemplares similares